Clinical trials (NCT00798655, NCT04810585, NCT02329639) are examining the potential of CXCL8 as a biomarker for therapy response and prognosis in a panel of different cancers; which would hopefully include EOC in the near future. The gene discussed is CXCL8; the disease is cancer.